Last reviewed · How we verify
NCT05519397
Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy
trial testing Immune checkpoint measurement in Breast Cancer in 56 participants. Completed in 1 October 2022.
1 September 2022
Quick facts
| Lead sponsor | Istanbul Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 January 2022 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Immune checkpoint measurement
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Istanbul Training and Research Hospital
Who can join
Adults 18 to 88, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer is the most common type of cancer in women and the second most common cause of death after lung cancer. In epidemiological studies, its prevalence is 22-26%, and the mortality risk due to breast cancer is around 18%. It is known that the immune system has an important role in tumor development or tumor destruction. Recent studies have shown that tumor cells acquire escape mechanisms to escape host immunity in the tumor microenvironment. Studies have reported that immune checkpoints are elevated in many types of cancer and have a poor prognosis. Up or down regulation of immune checkpoints is observed to protect breast cancer cells from the anti-tumor responses of the immune system. There are also immune checkpoints found in plasma in soluble form, and the number of studies evaluating soluble immune checkpoints in cancers is very limited in the literature. Measurement of soluble immune control points is easier than those expressed on the surface, and many markers can be evaluated at the same time. There are very few studies in the literature evaluating soluble immune checkpoints in breast cancer. The aim of this study is to investigate the role of soluble immune checkpoints in predicting the response to neoadjuvant therapy in locally advanced breast cancers.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.
Akinsipe T, Mohamedelhassan R, Akinpelu A, Pondugula SR, et al · · 2024 · cited 44× · PMID 38533507 · DOI 10.3389/fimmu.2024.1302587 -
It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.
Knickmeier C, Noubissi Nzeteu GA, Gibbs BF, Hoogwater FJH, et al · · 2025 · cited 5× · PMID 39958335 · DOI 10.3389/fimmu.2025.1495907
Verify or expand the search:
- PubMed search for NCT05519397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Istanbul Training and Research Hospital trials
Trials by the same sponsor.
- NCT07499713 — Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata · enrolling by invitation
- NCT07335822 — The Effectiveness of Low-Level Laser Therapy in the Treatment of Meralgia Paresthetica · NA · recruiting
- NCT07363187 — Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation · not yet recruiting
- NCT07415291 — CNN-Based AI Versus Physicians for Solitary Skin Lesion Diagnosis · active not recruiting
- NCT07150702 — Effects of Close Follow-up on Patients With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05519397 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Training and Research Hospital
- Last refreshed: 11 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05519397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing